Ozempic.Getty ImagesThe US economy will see a surge in growth as more people start to take GLP-1 weight loss drugs.Goldman Sachs forecasted that US GDP would jump by 1% if 60 million Americans took a GLP-1 drug."The main reason we see economic upside from healthcare innovation is that poor health imposes significant economic costs," Goldman Sachs said.The more people that take GLP-1 weight loss drugs, the faster the US economy will grow, according to estimates from Goldman Sachs.The bank said in a note on Thursday that US GDP would grow by an extra 1% if 60 million Americans took GLP-1 drugs by 2028.The thinking behind Goldman's forecast is that poor health is a burden for economic growth, as it can weigh heavily on the total labor supply and total hours worked through elevated "missed days" at work, early death, and informal caregiving that takes people out of the workforce."Combining current losses in hours worked and labor force participation from sickness and disability, early deaths, and informal caregiving, we estimate that GDP would potentially be over 10% higher if poor health outcomes did not limit labor supply in the US," Goldman Sachs economist Jan Hatzius said.So, a drug that has shown great promise in improving a wide range of health outcomes for patients could ultimately have a sizable impact on the broader economy."The main reason we see meaningful upside from healthcare innovation is that poor health imposes significant economic costs.

Topics:  getty imagesthe us   us goldman   jan hatzius   novo nordisk   eli lilly   wegovy   zepbound   if glp-1   business insider   ozempic   us   sachs   gdp   americans   glp-1   goldman   us gdp   dm    hatzius   hatzius   economy will grow   health   drugs   economic   poor   obesity   outcomes   million   weight   loss   growth   people   current   labor   significant   supply   total   estimates   excess   innovation   drug   reason   imposes   treat   productivity   main   related   costs   shown   upside   healthcare   output   work   worked   impact   informal   number   improving   caregiving   disability   hours   range   early   broader   wide   ultimately   estimate   
BING NEWS:
  • Ozempic vs Krispy Kreme: Wall Street firm bets weight-loss drugs won’t beat doughnut sales
    HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY Chappell said in a note that ... he noted how the $69 billion U.S. indulgent snack market has continued to grow. It ...
    06/11/2024 - 3:18 am | View Link
  • How Ozempic has a surprising financial benefit for Americans
    More people taking weight loss drugs could make the economy grow faster, according to a leading Goldman Sachs analyst.
    05/30/2024 - 3:24 am | View Link
  • Ozempic won't just make Americans slimmer
    More people taking weight loss drugs could make the economy grow faster, according to a leading Goldman Sachs analyst. If 60 million Americans took GLP-1 drugs - which include Ozempic - by 2028, US ...
    05/30/2024 - 2:06 am | View Link
  • The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says
    The more people who take GLP-1 weight-loss drugs, the faster the US economy could grow, a Goldman Sachs analyst ... are sold under the brand names Ozempic and Mounjaro to treat type 2 diabetes ...
    05/27/2024 - 7:08 am | View Link
  • The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says
    With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.
    05/27/2024 - 3:08 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News